Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease

BACKGROUND: Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. The remdesivir core contain...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Antimicrob Chemother
المؤلفون الرئيسيون: Avataneo, Valeria, de Nicolò, Amedeo, Cusato, Jessica, Antonucci, Miriam, Manca, Alessandra, Palermiti, Alice, Waitt, Catriona, Walimbwa, Stephen, Lamorde, Mohammed, di Perri, Giovanni, D’Avolio, Antonio
التنسيق: Artigo
اللغة:Inglês
منشور في: Oxford University Press 2020
الموضوعات:
Original Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7197584/
https://ncbi.nlm.nih.gov/pubmed/32361744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkaa152
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة